Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › New York

Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa New York keessatti

Qorannoo 26 Luukemiya Limfoositiikii Keessummaa f New York keessatti hirmaatuu jiru.

Magaalota New York keessatti

Takkalaa qorannoo (Ingiliffa)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

University of Rochester, Rochester
Wilmot Cancer Institute at Webster, Webster

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 65 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07321652

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute, Buffalo

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06863402

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin 40 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, New York
Research Site, New York

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Hematology Oncology Associates of CNY at Camillus, Camillus
Memorial Sloan Kettering Commack, Commack
Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse
fi 10 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Memorial Sloan Kettering Cancer Center Mskcc, New York
Optum Medical Care, Pc, Westbury

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Roswell Park Comprehensive Cancer Center, Buffalo
Columbia University Medical Center, New York
Weill Cornell Medical College Newyork Presbyterian Hospital, New York
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Columbia University Medical Center, New York

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07277231

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Memorial Sloan Kettering Cancer Center Mskcc, New York
New York Cancer and Blood Specialists, Shirley
Optum Medical Care, Pc, Westbury

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Columbia University Medical Center, New York
Weill Cornell Medical College Newyork Presbyterian Hospital, New York
Memorial Sloan Kettering Cancer Center Mskcc, New York
fi 1 dabalataa

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

New York Oncology Hematology, P.C. ( Site 5453), Albany

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

New York Oncology Hematology, P.C. ( Site 0069), Albany
Roswell Park Cancer Institute ( Site 0023), Buffalo
RPCI Oncology, PC- Northtowns ( Site 0061), Williamsville

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06136559

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Cayuga Cancer Center, Ithaca
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York

Namoota walitti qabaa jiraSadarkaa 4

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07218341

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07648264

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, New York

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06564038

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT03666000

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Memorial Sloan Kettering Cancer Center, New York

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06849713

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

New York Medical College, Valhalla

Namoota walitti qabaa jiraSadarkaa 1/2

Umuriin 13 hanga 90 · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT06533579

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

University of Rochester NCORP Research Base, Rochester

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Wax-2026 · NCT07638007

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Icahn School of Medicine at Mount Sinai /ID# 266328, New York

Namoota walitti qabaa jiraSadarkaa 3

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Elb-2026 · NCT06428019

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

Namoota walitti qabaa jiraSadarkaa 2

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT07218510

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Northwell Health, Lake Success
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York

Namoota walitti qabaa jiraSadarkaa 4

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Bit-2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Cayuga Cancer Center, Ithaca
Northwell Health, Lake Success
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York
fi 2 dabalataa

Namoota walitti qabaa jiraSadarkaa 4

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Bit-2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

Roswell Park Comprehensive Cancer Center, Buffalo
Weill Cornell, New York
Montefiore Medical Center, The Bronx

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2026 · NCT05544019

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Optum Medical Care PC, Westbury

Namoota walitti qabaa jiraSadarkaa 1

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Mud-2025 · NCT05602363

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park

Namoota walitti qabaa jira

Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2025 · NCT05643235

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.